Close Menu

NEW YORK ─ AnchorDx said on Thursday that it has entered into a multi-year collaboration with the Lung Cancer Initiative at Johnson & Johnson to conduct a four-year study to enable the early detection and diagnosis of lung cancer. Specifically, the agreement is with Johnson & Johnson (China) Investment.

Investigators will enroll and track the progress of more than 3,000 patients with pulmonary nodules identified by computed tomography scanning, according to AnchorDx, a developer of next-generation sequencing-based early cancer detection and disease monitoring tests.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Wall Street Journal, the Food and Drug Administration may soon issue an Emergency Use Authorization for convalescent plasma to treat COVID-19 patients.

Minnesota police have used genetic genealogy to make an arrest in a 1986 cold case, reports NBC News.

Researchers have used CRISPR-Cas9 to efficiently target a cephalopod pigmentation gene, as they report in Current Biology.

In Science this week: chromatin accessibility of microglia during fetal development, and more.